Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Short-term Investments: 2019-2025

Historic Short-term Investments for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $392.7 million.

  • Kymera Therapeutics' Short-term Investments fell 10.59% to $392.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.7 million, marking a year-over-year decrease of 10.59%. This contributed to the annual value of $368.5 million for FY2024, which is 39.10% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Short-term Investments is $392.7 million, which was up 19.14% from $329.6 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Short-term Investments ranged from a high of $442.3 million in Q2 2024 and a low of $264.9 million during Q4 2023.
  • In the last 3 years, Kymera Therapeutics' Short-term Investments had a median value of $368.5 million in 2024 and averaged $361.5 million.
  • Per our database at Business Quant, Kymera Therapeutics' Short-term Investments skyrocketed by 58.70% in 2024 and then dropped by 25.48% in 2025.
  • Over the past 5 years, Kymera Therapeutics' Short-term Investments (Quarterly) stood at $394.4 million in 2021, then declined by 14.11% to $338.8 million in 2022, then declined by 21.80% to $264.9 million in 2023, then skyrocketed by 39.10% to $368.5 million in 2024, then declined by 10.59% to $392.7 million in 2025.
  • Its Short-term Investments stands at $392.7 million for Q3 2025, versus $329.6 million for Q2 2025 and $373.2 million for Q1 2025.